PPD SEC Filings

Type
Report
Date
UPLOADUPLOAD-Formular7/28/2020
10-KJahresbericht3/5/2020
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben3/4/2020
4Insidertransaktion2/21/2020
4Insidertransaktion2/21/2020
4Insidertransaktion2/21/2020
4Insidertransaktion2/21/2020
4Insidertransaktion2/21/2020
4Insidertransaktion2/21/2020
4Insidertransaktion2/21/2020
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben2/18/2020
4Insidertransaktion2/12/2020
4Insidertransaktion2/12/2020
4Insidertransaktion2/12/2020
4Insidertransaktion2/12/2020
4Insidertransaktion2/12/2020
4Insidertransaktion2/12/2020
4Insidertransaktion2/12/2020
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben2/11/2020
424B4424B4-Formular2/6/2020
CERTCERT-Formular2/6/2020
S-8S-8-Formular2/6/2020
EFFECTEFFECT-Formular2/5/2020
33-Formular2/5/2020
33-Formular2/5/2020
33-Formular2/5/2020
33-Formular2/5/2020
33-Formular2/5/2020
33-Formular2/5/2020
33-Formular2/5/2020
33-Formular2/5/2020
33-Formular2/5/2020
33-Formular2/5/2020
33-Formular2/5/2020
8-A12B8-A12B-Formular2/5/2020
CORRESPCORRESP-Formular2/3/2020
S-1/AS-1/A-Formular1/27/2020
CORRESPCORRESP-Formular1/24/2020
UPLOADUPLOAD-Formular1/23/2020
CORRESPCORRESP-Formular1/23/2020
CORRESPCORRESP-Formular1/16/2020
S-1/AS-1/A-Formular1/16/2020
UPLOADUPLOAD-Formular1/10/2020
S-1S-1-Formular1/9/2020
UPLOADUPLOAD-Formular12/13/2019
15-12B15-12B-Formular7/11/2011
25-NSE25-NSE-Formular7/1/2011
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben6/30/2011
S-8 POSS-8 POS-Formular6/30/2011
S-8 POSS-8 POS-Formular6/30/2011
S-8 POSS-8 POS-Formular6/30/2011
10-K/A10-K/A-Formular6/29/2011
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben6/27/2011
DEFA14ADEFA14A-Formular6/14/2011
DEFA14ADEFA14A-Formular6/2/2011
DEFM14ADEFM14A-Formular5/13/2011
DEFA14ADEFA14A-Formular5/13/2011
PRER14APRER14A-Formular5/9/2011
10-K/A10-K/A-Formular4/29/2011
10-QQuartalsbericht4/27/2011
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben4/25/2011
SC 13E3SC 13E3-Formular4/18/2011
PRER14APRER14A-Formular4/18/2011
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben4/5/2011
SC 13D/ASC 13D/A-Formular11/1/2010
10-QQuartalsbericht10/27/2010
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben10/25/2010
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben10/25/2010
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben10/4/2010
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben8/26/2010
10-QQuartalsbericht7/21/2010
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben7/2/2010
ARSARS-Formular4/13/2010
UPLOADUPLOAD-Formular12/28/2009
UPLOADUPLOAD-Formular11/19/2009
UPLOADUPLOAD-Formular10/26/2009
UPLOADUPLOAD-Formular9/25/2009
UPLOADUPLOAD-Formular8/11/2009
10-K/A10-K/A-Formular6/30/2008
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben6/9/2008
10-QQuartalsbericht4/29/2008
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben4/28/2008
ARSARS-Formular4/16/2008
DEF 14ADEF 14A-Formular4/7/2008
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben4/2/2008
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben10/24/2007
10-QQuartalsbericht10/23/2007
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben10/3/2007
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben10/1/2007
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben9/12/2007
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben8/14/2007
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben8/1/2007
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben7/26/2007
10-QQuartalsbericht7/24/2007
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben7/3/2007
10-K/A10-K/A-Formular6/28/2007
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben4/27/2007
10-QQuartalsbericht4/23/2007
ARSARS-Formular4/10/2007
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben4/3/2007

PPD Documents 2026

This page contains all official documents and SEC filings for PPD stock (PPD, ISIN: US69355F1021). This includes annual reports (Form 10-K), quarterly reports (Form 10-Q), and insider transactions (Form 4). Currently 100 documents are available. Data is updated regularly to provide investors with a complete overview of PPD's regulatory filings.

PPD Stock analysis

PPD PPD Inc is a global company for medical research and services that was founded in 1985 and is headquartered in Wilmington, North Carolina, USA. The company is known for its ability to conduct clinical trials and develop research programs for the biopharmaceutical and medical industry. PPD is a leading provider of comprehensive, integrated services for phases I-IV of clinical research, from non-interventional studies to contract research for pharmaceutical and biotech clients. PPD's business model is based on three key pillars to provide customers with a broad portfolio of services: the first pillar is comprehensive clinical research required for drug registration with regulatory authorities, the second pillar focuses on providing research-based data and analytical methods to facilitate decision-making and risk assessment in the healthcare sector, and the third pillar encompasses extensive laboratory analyses and diagnostic tests to improve patient health and support research efforts. PPD has multiple divisions focused on specific markets and customers. The Clinical Trials division offers services for drug development up to approval by regulatory authorities, including the setup and monitoring of clinical trials and statistical analysis of test results. The Data Management division provides data capture and management solutions for clinical trials to ensure high data quality and compliance with regulations. The Medical Monitoring division offers medical consultation and monitoring during clinical trials. PPD also has a division for Real World Evidence studies, which collects data from routine clinical practice to assess the safety and efficacy of drugs. PPD has made some important acquisitions in the past to strengthen its presence in the industry. In 2011, PPD was acquired by private equity firms Carlyle Group and Hellman & Friedman, becoming a private company. In 2020, PPD went public. In 2018, PPD acquired Evidera, a company specializing in clinical epidemiology and outcomes research. In 2019, PPD acquired Q-Squared Solutions, expanding its extensive laboratory analysis and diagnostic testing capabilities. PPD's offerings include a wide range of products and services, including unique planning and implementation solutions that enable efficient conduct of clinical trials. These solutions also include electronic data capture and management systems, as well as statistical analysis tools. PPD also offers specialized services, such as training programs for clinical investigators and staff. PPD aims to enable safe, faster, and cost-effective drug development through clinical research. In the future, PPD will continue to expand its business model and services to meet the needs of its customers in the changing industry and support innovative research programs.